GlobeNewswire by notified

Notice of third quarter 2019 results and conference call

Share

Notice of third-quarter 2019 results and conference call  

Luxembourg, 20 September 2019Millicom will announce its third-quarter results for the period ending 30 September 2019, on 23 October 2019 at approximately 22:00 (Stockholm) / 21:00 (London) / 16:00 (Miami) via a press release.

The company will host a conference call for the global financial community on 24 October 2019 at 15:00 (Stockholm) / 14:00 (London) / 09:00 (Miami).

The conference call will be webcast at www.millicom.com

Dial-in information:

Please dial in 5-10 minutes before the scheduled start time to register your attendance. Dial-in numbers for the call are as follows:

Sweden:          +46 (0) 8 5069 2180                            Luxembourg:  +352 2786 0515

UK:                  +44 (0) 844 571 8892                          US:                   +1 866 966 1396

The access code is: 9380844

Replay information:

A replay of the call will be available for 7 days from 24 October 2019 at:

UK: +44 (0) 333 300 9785                   US: +1 (917) 677-7532

The access code is: 9380844

-END-

For further information, please contact

Press:
Vivian Kobeh, Corporate Communications Director
+1-786-628-5300
press@millicom.com

 

 

 
Investors:
Michel Morin, VP Investor Relations
+1-786-628-5270
investors@millicom.com




Sarah Inmon, Investor Relations Manager
+1-786-628-5303
investors@millicom.com

About Millicom

Millicom (NASDAQ U.S.: TIGO, Nasdaq Stockholm: TIGO_SDB) is a leading provider of cable and mobile services dedicated to emerging markets in Latin America and Africa. Millicom sets the pace when it comes to providing high-speed broadband and innovation around The Digital Lifestyle services through its principal brand, TIGO. As of December 31st, 2018, Millicom operating subsidiaries and joint ventures employed more than 21,000 people and provided mobile services to approximately 50 million customers, with a cable footprint of more than 11 million homes passed. Founded in 1992, Millicom International Cellular S.A. is headquartered in Luxembourg.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Prosafe SE: Annual reporting for 202319.3.2024 12:18:40 CET | Press release

Today, Prosafe publishes its Annual report, Transparency Act Statement and Remuneration report for 2023. The Annual report for 2023 includes the annual accounts, the sustainability report and the corporate governance report. The reports are attached and also available on https://www.prosafe.com/investor-information/annual-reports/ and on https://newsweb.oslobors.no/ Prosafe has also published its annual financial statements in European Single Electronic Format (ESEF), available as an attachment to this release. Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to www.prosafe.com Stavanger, 28 March 2023 Prosafe SE For further information, please contact: Terje Askvig, CEO Phone: +47 952 03 886 Reese McNeel, CFO Phone: +47 415 08 186 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading A

Danske Bank A/S, ledende medarbejderes transaktioner19.3.2024 12:08:46 CET | pressemeddelelse

19. marts 2024 Indberetning nr. 24/2024 Ændring i aktiebesiddelser hos Danske Banks indberetningspligtige i henhold til EU-forordningen om markedsmisbrug I forbindelse med Danske Bank A/S’ aktietilbagekøbsprogram sælger APMH Invest A/S løbende aktier i Danske Bank A/S pro rata. For yderligere detaljer henvises til de vedhæftede skemaer, hvori transaktioner udført af personer med ledelsesansvar og personer med nær tilknytning til disse skal indberettes og offentliggøres. Kontakt: Stefan Singh Kailay, Head of Media Relations, tel. +45 45 14 14 00 Vedhæftet fil APMH Invest A_S - salg - 2024-03-18

Danske Bank A/S, transactions by persons discharging managerial responsibilities19.3.2024 12:08:46 CET | Press release

19 March 2024 Notification no. 24/2024 Transactions made by persons obliged to report transactions to the Danish FSA and Nasdaq Copenhagen, cf. the EU Market Abuse Regulation. In connection with the share buy-back program in Danske Bank A/S, APMH Invest A/S continuously sells shares pro rata. For further details, please find the attached templates for notifications and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. Contact: Stefan Singh Kailay, Head of Media Relations, tel. +45 45 14 14 00 Attachment APMH Invest AS - sale - 2024-03-18

SPEVIGO® approved for expanded indications in China and the US19.3.2024 12:00:00 CET | Press release

Generalized pustular psoriasis (GPP) is a rare, chronic, heterogenous neutrophilic inflammatory disease associated with skin and systemic symptoms, such as fever, pain, and fatigue1,2,3,4In China, SPEVIGO®’s expanded approval adds the reduction of occurrences of GPP in pediatric patients aged 12 and above weighing ≥40 kg, and adults5The US FDA’s approval expands the use of SPEVIGO® to include the treatment of GPP in adults and pediatric patients aged 12 and above weighing ≥40 kg, making it the first targeted therapy that addresses the need for acute and chronic treatment for GPP patients6SPEVIGO® is currently approved in 48 countries7 Boehringer Ingelheim today announced that the US Food and Drug Administration (FDA) has approved SPEVIGO® (spesolimab-sbzo) injection for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients aged 12 and above weighing ≥40 kg.5 This approval follows the Chinese National Medical Products Administration’s (NMPA) recent appro

Equinor ASA: Kjøp av aksjer til aksjeprogram for ansatte19.3.2024 11:57:54 CET | Pressemelding

Nedenfor følger informasjon om transaksjoner knyttet til tilbakekjøpsprogrammet for Equinor ASA (OSE:EQNR, NYSE:EQNR) til bruk i aksjebaserte insentivprogrammer for ansatte og ledelse. Dato for annonsering av tilbakekjøpsprogrammet: 7. februar 2024. Varighet av tilbakekjøpsprogrammet: 15. februar 2024 til 15. januar 2025. Størrelse av tilbakekjøpsprogrammet: Samlet kjøpesum i tilbakekjøpsprogrammet er inntil NOK 1.156.000.000 og det maksimale antall aksjer som kan erverves er 16.800.000, hvorav opp til 7.400.000 aksjer kan erverves i perioden fra 15. februar 2024 til 15. mai 2024, og opptil 9.400.000 aksjer kan erverves i perioden fra 16. juni 2024 til 15. januar 2025. Den 15. mars 2024 kjøpte Equinor ASA totalt 482.159 egne aksjer ved Oslo Børs til en gjennomsnittspris på NOK 279,9906 pr. aksje. Oversikt over transaksjoner: DateAggregert volum (antall aksjer)Vektet gjennomsnittspris pr. aksje (NOK) Total transaksjonsverdi (NOK) 15 mars 2024482.159279,9906134.999.988Totalt tidligere of

HiddenA line styled icon from Orion Icon Library.Eye